NDA median approval time is shortened by 7% to 15.4 months in 1996.
Executive Summary
FDA 1996 MEDIAN NDA APPROVAL TIME OF 15.4 MONTHS IS 7% FASTER than the 1995 median time of 16.5 months, according to an analysis of 1996 review data released by FDA on Jan. 14. FDA approved 131 NDAs in 1996, a 60% increase over 1995's 82 NDAs. With eight biological approvals bringing the total number of new products approved to 139, FDA approved 63% more drugs and biologicals in 1996 than in 1995, when 85 new products were approved.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: